Introduction {#Sec1}
============

Traumatic brain injury (TBI) occurs when an external force injures the brain. Motor vehicle accidents cause most TBIs in young adults, while falls are the leading cause of TBIs in people over 65 years of age \[[@CR1]\]. Owing to the increasing use of motor vehicles in developed countries, the incidence of TBI is rapidly growing. TBI is a major cause of death and disabilities---especially in children and young adults---that result in high societal costs \[[@CR1], [@CR2]\]. Men sustain TBIs more frequently than women do. These observations suggest that TBIs result in major health and socioeconomic problems throughout the world. Indeed, the World Health Organization has reported that traffic accidents are the third highest contributor to the global burden of disease and injury \[[@CR1], [@CR2]\].

Neurological damage occurs not only at the moment of impact (primary injury) in a TBI, but also it further develops overtime post-impact. Several processes, such as neurotransmitter release, free-radical generation, calcium-mediated damage, gene activation, mitochondrial dysfunction, and inflammatory responses, have been investigated in studies of the secondary injuries that are associated with TBI \[[@CR3]--[@CR5]\]. These mechanisms might occur continuously over patients' lifetimes. Interestingly, a history of TBI has been reported to increase the incidence of Alzheimer disease (AD) \[[@CR6]\] and other neurodegenerative conditions, including Parkinson's disease (PD) \[[@CR7]\], amyotrophic lateral sclerosis (ALS) \[[@CR8]\], and frontotemporal dementia (FTD) \[[@CR5]\]. However, other studies have yielded contradicting results \[[@CR9]--[@CR13]\].

The goal of our study was to determine whether TBI was associated with an increased risk of neurodegeneration by conducting a systematic review of cohort studies of patients with TBI. In addition, we examined which neurodegenerative process occurred most often.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

We conducted systematic literature searches of the association between neurodegeneration and TBI in the Medical Literature Analysis and Retrieval System Online (MEDLINE®)/PubMed (US National Library of Medicine, National Institutes of Health, Bethesda, MD; <http://www.ncbi.nlm.nih.gov/pubmed>) database and Excerpta Medica Database (EMBASE®, Elsevier, Amsterdam, Netherlands; <http://www.elsevier.com/solutions/embase-biomedical-research>). We used the following keywords to generate a list of potentially useful studies: (\[traumatic brain injury\] OR \[head injury\] OR \[brain injury\] OR \[TBI\]) AND (\[neurodegeneration\] OR \[cognitive dysfunction\] OR \[dementia\] OR \[alzheimer's disease\] OR \[AD\] OR \[parkinson's disease\] OR \[parkinsonism\] OR \[frontotemporal dementia\] OR \[Amyotrophic Lateral Sclerosis\]) \[[@CR14]--[@CR16]\]. The search was performed through December 2016. The reference lists in the selected studies, as well as the list of studies included in earlier meta-analyses on similar topics, were reviewed for additional references. This review considered observational studies, and case series.

Inclusion criteria {#Sec4}
------------------

We included published articles on the risk of neurodegeneration, including cognitive dysfunction, dementia, AD, PD, FTD, and ALS, among individuals with TBIs compared with the risk of neurodegeneration in individuals in a nonbrain-injured population-based control group. A risk estimate was calculated with the data provided in the article. TBI was not limited in accordance with its severity.

Exclusion criteria {#Sec5}
------------------

Studies were excluded if (1) they were reviews, case reports, or case series; (2) they only consisted of a follow-up study of a cohort of patients with brain injury with no comparison group; (3) there was a non-population-based control group (i.e., a patient control group); or (4) insufficient information was available to allow for calculations of risk estimates \[[@CR14]--[@CR16]\].

Study selection {#Sec6}
---------------

The outcomes recorded were neurodegeneration, dementia, PD, and transactive response DNA-binding protein of 43 kDa (TDP-43) aggregation-associated disease. ALS and FTD, which are closely related conditions with overlapping clinical, pathological, radiological, and genetic characteristics, are characterized by TDP-43 aggregation \[[@CR17]\]. Therefore, we defined ALS and FTD as TDP-43-associated diseases. Two authors (H.K. Wang or Y.C. Tai) examined the titles and abstracts of the studies found in the systematic literature search. The entire articles of potentially eligible studies were assessed to determine if the studies met the criteria. The study selection process was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and documented with a PRISMA flow diagram.

Data analysis {#Sec7}
-------------

The effects of TBI on the neurodegeneration outcomes were assessed with a random effects model because the designs and patient populations of the observational studies were expected to be heterogeneous. The Odds Ratio (OR) and 95% confidence intervals (CIs) were calculated. Statistical heterogeneity was examined with chi-square and I-squared (I^2^) tests of heterogeneity. The data were analyzed with Review Manager (RevMan) Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).

Results {#Sec8}
=======

The systematic search {#Sec9}
---------------------

Using the search terms, our literature and reference list searches yielded 1317 references. After examination of the abstracts and, when indicated, the full texts of the articles, 68 studies were considered potentially relevant \[[@CR18]--[@CR37]\] . Finally, 18 studies met our inclusion criteria and were included in the meta-analysis. The characteristics of the included trials are listed in Table [1](#Tab1){ref-type="table"}. Methodologic qualities of are shown in Table [2](#Tab2){ref-type="table"}.Table 1Individual for all included studiesRefAuthor, yearTypeTBI+ Neurodegeneration +TBI+ Neurodegeneration -TBI- Neurodegeneration +TBI- Neurodegeneration -20Mehta KM, et al. 1999Dementia (APOE)11788118572821Luukinen H, et al. 2005532911522Sundström A, 2007254615631623Luukinen H, et al. 20081117149225Wang HK, 2012Dementia119643,7293499221,18626Gardner RC, et al. 2014436147,4386610108,89127Nordström P, et al.201410845,141458765,91528Abner EL, et al. 201481583145229Rasmusson DX, et al. 1995AD201483330Nemetz PN, et al. 1999311252957278331Barnes DE, et al. 20141212171098186,43732Spangenberg S, et al. 2009Parkinson8773,23287692,799,43433Lee PC, et al. 2012425031570434Taylor KM, et al. 2015692431020635Gardner RC, et al. 201589151,5021247112,15936Kalkonde YV, 2012FTD (TDP-43)817554745Wang HK, et al. 201536324,222413122,51237Chen H, et al. 2007ALS (TDP-43)244285213Table 2Consensus ACROBAT-NRSI judgments between two reviewers by domain of biasComponent StudyDomainOverall RoB BiasBias Due to Judgment ConfoundingBias in Selection of ParticipantsBias in Measurement of InterventionsBias Due to Departures from Intended InterventionsBias in Measurement of OutcomesBias in Selection of Reported ResultsBias Due to Missing DataMehta KM, et al. \[[@CR20]\]moderatemoderatelowlowlowlowlowmoderateLuukinen H, et al. \[[@CR21]\]lowlowlowlowlowlowlowlowSundström A, \[[@CR22]\]lowlowlowlowlowlowlowlowLuukinen H, et al. \[[@CR23]\]lowlowlowlowlowlowlowlowWang HK, \[[@CR25]\]lowmoderatelowlowmoderatelowlowlowGardner RC, et al. \[[@CR26]\]lowmoderatelowlowmoderatelowlowlowNordström P, et al. \[[@CR27]\]lowmoderatelowlowmoderatelowlowlowAbner EL, et al. \[[@CR28]\]lowmoderatelowlowmoderatelowlowlowRasmusson DX, et al. \[[@CR29]\]lowlowlowlowlowlowlowlowNemetz PN, et al. \[[@CR30]\]lowmoderatelowlowmoderatelowlowlowBarnes DE, et al. \[[@CR31]\]lowmoderatelowlowmoderatelowlowlowSpangenberg S, et al. \[[@CR32]\]lowlowlowlowlowlowlowlowLee PC, et al. \[[@CR33]\]lowlowlowlowlowlowlowlowTaylor KM, et al. \[[@CR34]\]lowlowlowlowlowlowlowlowGardner RC, et al. \[[@CR35]\]lowmoderatelowlowmoderatelowlowlowKalkonde YV, \[[@CR36]\]lowlowlowlowlowlowlowlowWang HK, et al. \[[@CR5]\]lowmoderatelowlowmoderatelowlowlowChen H, et al. \[[@CR37]\]lowlowlowlowlowlowlowlow

The subgroup meta-analyses {#Sec10}
--------------------------

There was an association between TBI and subsequent dementia (pooled OR = 1.93, 95% CI = 1.47--2.55) (Fig. [1](#Fig1){ref-type="fig"}). However, this association does not concur with the apolipoprotein E (APOE) genotype (pooled OR = 1.82, 95% CI = 0.74--4.46) (Fig. [2](#Fig2){ref-type="fig"}). The studies associated with AD yielded a pooled OR of 1.03 (95% CI = 0.06--16.33) with heterogeneity (I^2^ = 98%, *P* \< 0.001) (Fig. [3](#Fig3){ref-type="fig"}). The analysis of the risk of TBI that was associated with PD yielded a pooled OR of 1.19 (95% CI = 0.50--2.84) with heterogeneity (I^2^ = 98%, P \< 0.001) (Fig. [4](#Fig4){ref-type="fig"}). The analysis of the risk associated with TDP-43 and FTD yielded a pooled OR of 2.97 (95% CI = 1.35--6.53) and 4.44 (95% CI = 3.86--5.10) (Figs. [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"}).Fig. 1Individual and pooled odds ratios for dementiaFig. 2Individual and pooled odds ratios for dementia with APOEFig. 3Individual and pooled odds ratios for Alzheimer's Disease (AD)Fig. 4Individual and pooled odds ratios for Parkinson's Disease (PD)Fig. 5Individual and pooled odds ratios for transactive response DNA-binding protein of 43 kDa (TDP-43)Fig. 6Individual and pooled odds ratios for frontotemporal dementia (FTD)

Discussion {#Sec11}
==========

Concerns about the relationship between TBI and neurodegeneration have long existed. Our principal finding was that TBI is a potential risk factor for subsequent dementia (1.93, 95% CI = 1.47--2.55), TDP-43 (2.97, 95% CI = 1.35--6.53) and FTD (4.44, 95% CI = 3.86--5.10). However, when we analyzed the associations of the incidences of AD, PD, or dementia with APOE genotype, we found that TBI was not a risk.

A common factor between TBI and different neurodegenerative disorders is the abnormal aggregation, accumulation, and/or disposition of proteins in the brain. Patients with TBI have beta-amyloid deposition in their brains, and the pattern of deposition is similar to that observed in patients with AD. Amyloid precursor protein, β-Amyloid precursor protein-cleaving enzyme-1, and presenilin-1, which is a γ-secretase complex protein, serve as sources of amyloid-β peptide deposition after TBI \[[@CR5], [@CR29]--[@CR31]\].

TBI may also exacerbate nigrostriatal dopaminergic degeneration by modulating PD-associated genes. These results suggest that α-synuclein is a pathological link between the chronic effects of TBI and PD symptoms \[[@CR32]--[@CR34]\].

Another mechanism that might link TBI to neurodegeneration is the accumulation of TDP-43 in patients with FTD and ALS \[[@CR5], [@CR24], [@CR37]\]. Patients with chronic traumatic encephalopathy (CTE) exhibit widespread TDP-43 proteinopathy in multiple areas of the brain \[[@CR38]\]. Some patients also had TDP-43 protein in their spinal cords, and these patients developed a progressive motor neuron disease several years before their deaths \[[@CR38], [@CR39]\]. These findings suggest that TDP-43-associated neurodegeneration and head trauma are connected.

The mechanisms underlying the association of TBI and the incidence of neurodegeneration are exceedingly complex. In fact, in TBI, multiple pathologies occur simultaneously. However, systematic analyses of multiple pathologies in individual cases in a large TBI and control population have not been conducted \[[@CR9]--[@CR13], [@CR39]\]. Therefore, a significant association of AD, PD, and APOE-associated dementia was not observed, and no evidence that head trauma was a risk factor for patients with these disorders was found.

Another noteworthy finding of our study was that AD is not the most common form of neurodegeneration. Several studies have reported that TBI does not affect the development of AD. Whether a single occurrence of moderate-to-severe TBI triggers the development of neurodegeneration remains somewhat controversial \[[@CR9]--[@CR13]\]. In addition, brain injury has been shown to lead to the development of non-AD dementias. However, accurate clinical diagnostic criteria for neurodegeneration that results from TBI do not exist. Therefore, the true risk of neurodegeneration following TBI is hard to define.

Examinations of patients with CTE may help resolve this problem. The symptoms of CTE, which include behavioral disturbances, cognitive dysfunction, and/or motor-related symptoms, generally begin 8--10 years after repetitive mild TBIs are experienced \[[@CR40]--[@CR42]\]. However, the clinical diagnostic criteria for traumatic encephalopathy syndrome have only recently been reported. CTE can be seen after a single moderate or severe TBI while traumatic encephalopathy syndrome exhibits progressive deterioration over time. Therefore, clinical judgment must be used to determine whether the amount of progression is greater than what is expected for the age and comorbidities of the patient \[[@CR39]--[@CR42]\]. Multiple neurodegeneration processes have been used to describe the behavioral disturbances and cognitive dysfunction in patients following TBI owing to the lack of suitable diagnoses. This diagnosis can now be used to define those symptoms.

A major strength of this meta-analysis was the inclusion of a variety of different neurodegenerative outcomes rather than a single diagnosis. The literature search was comprehensive because it focused on diagnoses rather than self-reported symptoms, which resulted in a rigorous examination of the topic.

However, several limitations of this meta-analysis warrant consideration. First, the initial severities of the TBIs varied within and across studies. Since our meta-analyses examined only published data, some important parameters, such as sex, alcohol consumption, and comorbidities were missing. Therefore, we were not able to control for these potential confounding factors. Patients with severe TBI had loss of high cortical function and presented in a vegetative state. In our studies, we included only patients who sought treatment for TBI and neurodegeneration disease, but not important parameters indicating clinical severity and imaging information on TBI. Therefore, it is hard to understand the relationship between the severity of TBI and neurodegeneration disease.

Second, we were not able to examine the effects of the locations of the TBIs in this analysis. Some investigators have proposed that temporal and frontal lobe lesions are more likely to be associated with an increased risk of later dementia compared with lesions in other brain regions \[[@CR5]\]. In addition, preinjury intelligence and education level are also associated with TBI and dementia. However, the effects of these factors in this study were difficult to determine.

Another limitation was that none of the studies included in this review provided information on genetics \[[@CR8]\]. The estimated effect of the apolipoprotein E (*APOE*) gene 4 on functional outcome might be greatly confounded by such factors, which could thus influence the validity of any meta-analysis that uses unadjusted results. Therefore, future studies on the relationship between *APOE 4* expression and the functional outcome of TBI should consider these important confounding factors. The age may also have an effect on the patients with neurodegeneration diseases. The risk between early-onset and late-onset neurodegeneration diseases maybe different. The patient with young onset neurodegeneration diseases more likely has a genetic or metabolic disease. However, neurodegeneration diseases are far more common in geriatric population, and researches in neurodegeneration disease are focused mainly on old persons. Therefore, it is hard to understand the association between age and neurodegeneration diseases in our study.

Conclusion {#Sec12}
==========

Patients with TBI frequently exhibit neurodegeneration. The symptoms of these neurodegenerative processes include behavioral disturbances, cognitive dysfunction, and/or motor-related symptoms. TBI is a potential risk factor only for subsequent dementia, TDP-43, and FTD, but not for AD, PD, or APOE-associated neurodegeneration. The epidemiology and pathology of this association have been difficult to establish. No suitable criteria define these neurodegenerative processes. However, the diagnosis of CTE may help to resolve this problem. Although the evidence suggested that TBI was a risk factor for neurodegeneration, there is limited information on the type, frequency, or amount of trauma that was necessary to induce the neurodegenerative processes. Therefore, further studies in this area are necessary to answer these questions and determine whether the proper management of TBI is effective in reducing the incidence of neurodegeneration.
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